title: Personalized medicine enters the US marketplace: KRAS, anti-EGFR monoclonal antibodies, and colon cancer.
authors.affiliation: Department of Hematology, Oncology and Transplantation, Quintiles, Inc, Rockville, MD 20852, USA. ronald.lieberman@quintiles.com
authors.forename: Ronald
authors.initials: R
authors.lastname: Lieberman
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D066246:ErbB Receptors / Q000037:antagonists & inhibitors* / Q000276:immunology; D005820:Genetic Testing; D006801:Humans; D040541:Marketing; D009154:Mutation; D018579:Patient Selection; D010597:Pharmacogenetics; D057285:Precision Medicine; D011518:Proto-Oncogene Proteins / Q000235:genetics*; D016283:Proto-Oncogene Proteins p21(ras); D016896:Treatment Outcome; D014481:United States; D018631:ras Proteins / Q000235:genetics*
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D066246:ErbB Receptors; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins